Compounds > proxazole
Page last updated: 2024-12-05

proxazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

proxazole: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID8590
CHEMBL ID2106997
CHEBI ID135191
SCHEMBL ID24319
MeSH IDM0047230

Synonyms (62)

Synonym
proxazole
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, (+)-
(+)-proxazole
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, (+-)-
(+-)-proxazole
(+)-5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, (+-)-
(-)-proxazole
(+-)-5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole
(-)-5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole
(+)-proxazolo [italian]
(-)-proxazolo [italian]
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, (-)-
(+-)-proxazolo [italian]
brn 0679871
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-, (-)-
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, (+)-
proxazole (usan/inn)
5696-09-3
D05644
CHEBI:135191
n,n-diethyl-2-[3-(1-phenylpropyl)-1,2,4-oxadiazol-5-yl]ethanamine
31363-10-7
5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole
proxazolum
proxazol
proxazole [usan:inn]
prossazolo [dcit]
proxazolum [inn-latin]
1,2,4-oxadiazole-5-ethanamine, n,n-diethyl-3-(1-phenylpropyl)-
fd72t13m0k ,
proxazol [inn-spanish]
prossazolo
unii-fd72t13m0k
j64jy9ah7h ,
unii-6mrd2sle7w
proxazole, (+)-
31363-09-4
6mrd2sle7w ,
proxazole, (-)-
(-)-proxazolo
(+)-proxazolo
unii-j64jy9ah7h
31363-08-3
(+-)-proxazolo
CHEMBL2106997
propoxaline
AKOS023249360
SCHEMBL24319
proxazole [mi]
proxazole [usan]
proxazole [who-dd]
proxazole [inn]
(+/-)-proxazole
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(.alpha.-ethylbenzyl)-
n,n-diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazol-5-ethanamin
DB13819
Q7252832
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(.alpha.-ethylbenzyl)-, (+)-
1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-(.alpha.-ethylbenzyl)-, (-)-
1h-imidazol-2-ylmethanolhydrochloride
DTXSID90859261
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (75.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.58 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (16.67%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
histidine
Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.		1.9510amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		2.8840
ConditionIndicatedRelationship StrengthStudiesTrials
Chronic Kidney Failure
[description not available]		01.9610
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		01.9610
Acute Kidney Failure
[description not available]		01.9510
Acute Kidney Injury
Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.		01.9510
Arterial Obstructive Diseases
[description not available]		01.9510
Arterial Occlusive Diseases
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.		01.9510
Arteriosclerosis Obliterans
Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.		01.9510
Intermittent Claudication
A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.		01.9510